Clinical guidance statements, recommendations, and meta-analyses are available for clinicians that provide direction on issues relating to the use of adjuvant endocrine therapy, and extended adjuvant (EA) endocrine therapy in patients with estrogen receptor-positive (ER+), early breast cancer (EBC). Here, ESR1 is linked to breast cancer.